Equity

Unrealized Losses on Investments (Before Tax)

Vertex Pharmaceuticals Unrealized Losses on Investments (Before Tax) decreased by 33.3% to $800.00K in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 33.3%, from $600.00K to $800.00K. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementBalance Sheet Statement
SectionEquity
CategoryRisk
SignalLower is better
VolatilityModerate
First reportedQ3 2018
Last reportedQ4 2025

How to read this metric

An increase suggests declining market value of the firm's investment holdings, which may negatively impact book value and regulatory capital.

Detailed definition

This metric tracks the total unrealized losses on investment securities, primarily available-for-sale assets, before acc...

Peer comparison

Standard disclosure for financial institutions to show the impact of market volatility on investment portfolios.

Metric ID: unrealized_losses_on_investments

Historical Data

8 periods
 Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25
Value$16.10M$24.20M$19.10M$23.40M$600.00K$2.20M$1.20M$800.00K
QoQ Change+50.3%-21.1%+22.5%-97.4%+266.7%-45.5%-33.3%
YoY Change+45.3%-97.5%-88.5%-94.9%+33.3%
Range$600.00K$24.20M
CAGR-82.0%
Avg YoY Growth-40.4%
Median YoY Growth-88.5%
Current Streak2 quarters decline

Frequently Asked Questions

What is Vertex Pharmaceuticals's unrealized losses on investments (before tax)?
Vertex Pharmaceuticals (VRTX) reported unrealized losses on investments (before tax) of $800.00K in Q3 2025.
How has Vertex Pharmaceuticals's unrealized losses on investments (before tax) changed year-over-year?
Vertex Pharmaceuticals's unrealized losses on investments (before tax) increased by 33.3% year-over-year, from $600.00K to $800.00K.
What does unrealized losses on investments (before tax) mean?
The total amount of loss on investments that the firm still holds and has not yet sold.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.